- Natural product: Goldenseal (Hydrastis canadensis)
- Associated study: R21 Goldenseal Project
In Vivo Interaction Study
Oral Metformin/Oral Inhibitor Mouse Study - Imatinib
Decreased systemic exposure was detected.
Results
Control:
-AUC0-4h: 4.7 (24)
-AUCR (ratio of AUC0-4h in presence of test article to vehicle; values represented as geometric means with 90% CI): N/A
-AUCR (ratio of AUC0-12h in presence of test article to vehicle; values represented as geometric means with 90% CI): N/A
Test:
-AUC0-4h: 3.7 (12)
-AUCR (ratio of AUC0-4h in presence of test article to vehicle; values represented as geometric means with 90% CI): 0.79 (0.65-0.96)
-AUCR (ratio of AUC0-12h in presence of test article to vehicle; values represented as geometric means with 90% CI): 0.89 (0.74-1.07)
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Blood was used for LC-MS analysis.
Single dosing
Males
FVB
8 per test group
The form has been tweaked for the mice study.
Study population: mice
Study population phenotype: Jackson laboratory (Bar Harbor, Maine)
0.25, 0.5, 1, 2, 4, 8, and 12 h
None
Drug or Natural Product Administration
Oral
Liquid
Metformin (10 mg/kg)
Single dose administered by oral gavage at 10 ml/kg for both goldenseal and other test articles.
Once
Oral
N/A
Imatinib (100 mg/kg)
Single dose administered by oral gavage at 10 ml/kg for both goldenseal and other test articles.
Once
Goldenseal
Yes - sent to Clarke lab by Dr. Oberlies at UNCG
N/A
Pharmacodynamics (PD) & Adverse Events
N/A
N/A
N/A